Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 18/20 | 0.53 |
| ▸ | DDB1 | Q16531 | 5/20 | 0.52 |
| ▸ | IKZF3 | Q9UKT9 | 3/20 | 0.52 |
| ▸ | TNF | P01375 | 2/20 | 0.52 |
| ▸ | IKZF1 | Q13422 | 2/20 | 0.52 |
| ▸ | BRD4 | O60885 | 1/20 | 0.52 |
| ▸ | IL1B | P01584 | 1/20 | 0.52 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.45 |
| ▸ | IKZF2 | Q9UKS7 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25650346 | 1.00 | CRBN (0.53) | CRBNDDB1IKZF3TNFIKZF1 | |
| SCHEMBL29636951 | 1.00 | CRBN (0.53) | CRBNDDB1IKZF3TNFIKZF1 | |
| SCHEMBL25012239 | 0.91 | CRBN (0.56) | CRBNDDB1IKZF3TNFIKZF1 | |
| SCHEMBL30270827 | 0.91 | CRBN (0.56) | CRBNDDB1IKZF3TNFIKZF1 | |
| SCHEMBL25650364 | 0.90 | CRBN (0.53) | CRBNDDB1IKZF3TNFIKZF1 | |
| SCHEMBL25650291 | 0.90 | CRBN (0.53) | CRBNDDB1IKZF3TNFIKZF1 | |
| SCHEMBL30270652 | 0.86 | CRBN (0.52) | CRBNDDB1IKZF3TNFIKZF1 | |
| SCHEMBL30270801 | 0.86 | CRBN (0.52) | CRBNDDB1IKZF3TNFIKZF1 | |
| SCHEMBL23066094 | 0.86 | CRBN (0.52) | CRBNDDB1IKZF3TNFIKZF1 | |
| SCHEMBL19451225 | 0.86 | CRBN (0.52) | CRBNDDB1IKZF3TNFIKZF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024130095-A1 | COMPOUNDS AND COMPOSITIONS AS CBP/P300 DEGRADERS AND USES THEREOF | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2024-06-20 | — | — | WO | disclosed |
| WO-2023104155-A1 | LIGAND COMPOUNDS FOR E3 UBIQUITIN LIGASE, PROTEIN DEGRADERS DEVELOPED ON BASIS OF LIGAND COMPOUNDS, AND USES THEREOF | 标新生物医药科技(上海)有限公司 | 2023-06-15 | — | — | WO | disclosed |
| US-11466028-B2 | Fused 1,4-oxazepines as BET protein degraders | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2022-10-11 | — | — | US | disclosed |
| EP-3512855-B1 | FUSED 1,4-OXAZEPINES AS BET PROTEIN DEGRADERS | UNIV MICHIGAN REGENTS (US) | 2022-07-27 | — | — | EP | disclosed |
| CN-110062759-B | Fused 1, 4-oxazepine as BET protein degrading agent | 密执安大学评议会 | 2022-05-24 | — | — | CN | disclosed |
| US-20210284657-A1 | FUSED 1,4-OXAZEPINES AS BET PROTEIN DEGRADERS | UNIV MICHIGAN REGENTS (US) | 2021-09-16 | — | — | US | disclosed |
| WO-2021126974-A1 | BIFUNCTIONAL AGENTS FOR PROTEIN RECRUITMENT AND/OR DEGRADATION | ORIONIS BIOSCIENCES, INC. (US) | 2021-06-24 | — | — | WO | disclosed |
| EP-3512855-A1 | FUSED 1,4-OXAZEPINES AS BET PROTEIN DEGRADERS | The Regents of the University of Michigan (US) | 2019-07-24 | — | — | EP | disclosed |
| WO-2018052945-A1 | FUSED 1,4-OXAZEPINES AS BET PROTEIN DEGRADERS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2018-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11466028-B2 | Fused 1,4-oxazepines as BET protein degraders | BRD4, BET1, BRD1 | CRBN 179/4885DDB1 425/4885IKZF3 232/4885 |
| US-20210284657-A1 | FUSED 1,4-OXAZEPINES AS BET PROTEIN DEGRADERS | BRD4, BET1, BRD1 | CRBN 179/4885DDB1 425/4885IKZF3 232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.